Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for atrial fibrillation
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrialfibrillation and heart failure. Heart failure (HF) is a common co-morbidity in non-valvular atrialfibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time-in-therapeutic range with warfarin. We assessed the real-world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co-morbid HF.Using US Truven MarketScan Commercial and Medicare
Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With AtrialFibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation Despite recommendations in the guidelines and consensus documents, there has been no randomized controlled trial evaluating oral anticoagulation (OAC) alone without antiplatelet therapy (APT) in patients with atrialfibrillation and stable coronary artery disease beyond 1 (...) year after coronary stenting.This study was a prospective, multicenter, open-label, noninferiority trial comparing OAC alone to combined OAC and single APT among patients with atrialfibrillation beyond 1 year after stenting in a 1:1 randomization fashion. The primary end point was a composite of all-cause death, myocardial infarction, stroke, or systemic embolism. The major secondary end point was a composite of the primary end point or major bleeding according to the International Society
Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrialfibrillation: insights from ARISTOTLE. We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrialfibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AtrialFibrillation (ARISTOTLE) study to better inform the care of these high-risk patients.Thrombo-embolic events were
General medicine: Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrialfibrillation Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrialfibrillation | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrialfibrillation Article Text Commentary General medicine Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrialfibrillation David Massicotte-Azarniouch 1 , Manish M Sood 1 , 2
A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrialfibrillation. Antiarrhythmic drugs (AADs) for the treatment of atrialfibrillation (AF) are associated with limited efficacy and adverse effects. Inhibition of the atrial current IKur, absent from the ventricle, is expected to be antiarrhythmic, without adverse cardiac effects, particularly ventricular pro-arrhythmic effects.A randomized clinical trial in symptomatic (...) related preclinical safety concerns, after 58 patients had been enrolled. The median AFB ranged from 4.3% to 10.3% at baseline in the four treatment groups. S66913 had no significant effect on AFB or on AFB plus atrial tachycardia (AT) burden, at any dosage; nor on any secondary endpoints including the number and duration of AT or AF episodes, and symptoms. The drug was well tolerated with no safety concern during the treatment or the extended clinical follow-up.DIAGRAF-IKUR was the first study
Development and validation of a score to detect paroxysmal atrialfibrillation after stroke Prolonged monitoring times (72 hours) are recommended to detect paroxysmal atrialfibrillation (pAF) after ischemic stroke but this is not yet clinical practice; therefore, an individual patient selection for prolonged ECG monitoring might increase the diagnostic yield of pAF in a resource-saving manner.We used individual patient data from 3 prospective studies (ntotal = 1,556) performing prolonged
Dialysis Modality and Incident AtrialFibrillation in Older Patients With ESRD Atrialfibrillation (AF) is common in patients with kidney failure treated by maintenance dialysis. Whether the incidence of AF differs between patients receiving hemodialysis and peritoneal dialysis is uncertain.Retrospective cohort study.Using the US Renal Data System, we identified older patients (≥67 years) with Medicare Parts A and B who initiated dialysis therapy (1996-2011) without a diagnosis of AF during
Relation of the CHA2DS2-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without AtrialFibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study) Recent hospital-based cohort studies found the CHA2DS2-VASc score to be associated with ischemic stroke in individuals without atrialfibrillation (AF). Our aim was to determine the distribution of embolic and thrombotic strokes and association with the CHA2DS2-VASc score, among community-dwelling
Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in AtrialFibrillation? A Report from the Western Denmark Heart Registry Patients with atrialfibrillation (AF) have an increased risk of ischaemic stroke. The risk can be predicted by the CHA2DS2-VASc score, in which the vascular component refers to previous myocardial infarction, peripheral artery disease and aortic plaque, whereas coronary artery disease (CAD) is not included. This article
AtrialfibrillationAtrialfibrillation - NICE CKS Share Atrialfibrillation: Summary Atrialfibrillation (AF) is an arrhythmia. It results from irregular, disorganized electrical activity in the atria, leading to an irregular ventricular rhythm. The ventricular rate of untreated AF often averages between 160–180 beats per minute (although this is typically slower in older people). The most common causes of AF are ischaemic heart disease, hypertension, valvular heart disease (...) Excellence (NICE) guideline: Atrialfibrillation: the management of atrialfibrillation [ ]. This CKS topic covers the management of people with atrialfibrillation (AF), including people with paroxysmal AF, and covers management issues such as rate control, anticoagulation treatment, and when to admit or refer to a cardiologist. This CKS topic does not cover the management of AF in children, AF during pregnancy, AF causing haemodynamic instability, postoperative AF, or atrial flutter. This guideline
Association Between Titin Loss-of-Function Variants and Early-Onset AtrialFibrillation. Atrialfibrillation (AF) is the most common arrhythmia affecting 1% of the population. Young individuals with AF have a strong genetic association with the disease, but the mechanisms remain incompletely understood.To perform large-scale whole-genome sequencing to identify genetic variants related to AF.The National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine Program includes
Antithrombotic Therapy for AtrialFibrillation: CHEST Guideline and Expert Panel Report Antithrombotic Therapy for AtrialFibrillation CHEST Guideline and Expert Panel Report Gregory Y. H. Lip, MD; Amitava Banerjee, MD, DPhil; Giuseppe Boriani, MD, PhD; Chern en Chiang, MD, PhD; Ramiz Fargo, MD, FCCP; Ben Freedman, MD, PhD; Deirdre A. Lane, PhD; Christian T. Ruff, MD, MPH; Mintu Turakhia, MD; David Werring, PhD; Sheena Patel, MPH; and Lisa Moores, MD, FCCP BACKGROUND (...) disease, age 65-74 and sex category ABBREVIATIONS: ABC = Atrial ?brillation Better Care; ACS = acute coronary syndrome; ACTIVE W = AtrialFibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events; ACUTE = Assessment of Cardioversion Using Transesophageal Echocardiog- raphy; AFFIRM= AtrialFibrillationFollow-upInvestigationofSinus Rhythm Management; AHRE = atrial high-rate episode; aPTT = activated partial thromboplastin time; ARISTOTLE = Apixaban for Reduction of Stroke and Other
Risk of Thromboembolism Associated With AtrialFibrillation Following Noncardiac Surgery The long-term risk of thromboembolism in patients developing new-onset post-operative atrialfibrillation (POAF) following noncardiac surgery is unknown, and data on stroke prophylaxis in this setting are lacking.The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular (...) atrialfibrillation (NVAF).Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes, previous thromboembolism, ischemic heart disease, and year of diagnosis to patients with nonsurgical NVAF in a 1:4 ratio. Comparative long-term risk of thromboembolism was examined by multivariable Cox regression models.In patients undergoing noncardiac surgery, 6,048
Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With AtrialFibrillation Sudden cardiac death (SCD), the most devastating manifestation of ventricular arrhythmias (VAs), is the leading cause of mortality in patients with atrialfibrillation (AF). We hypothesized that the CHA2DS2-VASc score, consisting of age and several clinical risk factors, could be used to estimate the individual risk of SCD/VAs for AF patients. From
Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid AtrialFibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study) We aim to determine the benefit of two different doses magnesium sulfate (MgSO4 ) compared to placebo in rate control of rapid atrialfibrillation (AF) managed in the emergency department (ED).We undertook a randomized, controlled, double-blind clinical trial in three university hospital EDs between August 2009 and December 2014. Patients
Is the Risk of Bleeding Among Older Adults With AtrialFibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? TAKE-HOME MESSAGE Older adults have a lower risk of any severity of bleeding (includes both major and minor bleeding) when treated with aspirin or clopidogrel compared to warfarin. However, if minor bleeding is excluded, only the subgroup of patients aged 80 years or older demonstrate a lower risk the of major bleeding with antiplatelet agents. Is the Risk of Bleeding (...) Among Older Adults With AtrialFibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? EBEM Commentators Cameron Gettel, MD Elizabeth M. Goldberg, MD, ScM Department of Emergency Medicine Alpert Medical School of Brown University Providence, RI Results Commentary Several systematic reviews have previously shown that the risk of bleeding with long-term treatment with aspirin was lower than with warfarin. 2,3 It is common clinical practice to use antiplatelet agents as alternatives
Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With AtrialFibrillation? (SRS Diagnosis) TAKE-HOME MESSAGE Multidetector computed tomography (CT) is a sensitive test to detect left atrial thrombus in patients with atrial ?brillation. Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With AtrialFibrillation? EBEM Commentators Christopher J. Solie, DO Nicholas M. Mohr, MD, MS Daniel P. Runde, MD Department of Emergency Medicine (...) cardioversion of atrial ?brillation? J Am Coll Cardiol. 1994;23:533-541. 6. Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography inpatients with atrialfibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013;6:185-194. 7. Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med. 1995;123:817-822. 8. Hwang JJ, Chen JJ
Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE In partnership with Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update October 2018Comparative Effectiveness Review Number 214 Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact email@example.com. Suggested citation: Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Allen LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S. Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update. Comparative Effectiveness Review No. 214. (Prepared
Standardized Library of AtrialFibrillation Outcome Measures Research White Paper Standardized Library of AtrialFibrillation Outcome Measures Research White Paper Standardized Library of AtrialFibrillation Outcome Measures Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2014-00004-C Prepared by: L&M Policy Research, LLC Washington, DC With partner: OM1, AcademyHealth (...) access information in this report. For assistance contact firstname.lastname@example.org. Suggested citation: Gliklich RE, Leavy MB, Li F. Standardized Library of AtrialFibrillation Outcome Measures. Research White Paper. (Prepared by L&M Policy Research, LLC under Contract No. 290-2014-00004-C.) AHRQ Publication No. 18(19)-EHC026-EF. Rockville, MD: Agency for Healthcare Research and Quality; November 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org
Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of AtrialFibrillation 2018 CCS Focused Update of the Guidelines for the Management of AtrialFibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Laurent Macle Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson, Servier Johnson & Johnson, Servier Atul Verma Bayer, Johnson & Johnson, Medtronic Johnson & Johnson Jason Andrade Bayer, BMS Pfizer, Medtronic, Servier (...) process. Below is a list of all disclosures for the AF panel, regardless of relevance to the 2018 AF Guideline Update. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Page 1 2018 CCS Focused Update of the Guidelines for the Management of AtrialFibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content